Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short-term Investments: 2020-2025

Historic Short-term Investments for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $143.9 million.

  • Arcutis Biotherapeutics' Short-term Investments fell 26.45% to $143.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.9 million, marking a year-over-year decrease of 26.45%. This contributed to the annual value of $156.6 million for FY2024, which is 14.63% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Short-term Investments stood at $143.9 million for Q3 2025, which was up 21.90% from $118.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Short-term Investments peaked at $395.4 million during Q3 2022, and registered a low of $118.1 million during Q2 2025.
  • Over the past 3 years, Arcutis Biotherapeutics' median Short-term Investments value was $163.6 million (recorded in 2023), while the average stood at $179.0 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Short-term Investments surged by 510.80% in 2021 and then slumped by 69.74% in 2023.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Short-term Investments stood at $290.6 million in 2021, then increased by 22.48% to $355.9 million in 2022, then slumped by 48.46% to $183.5 million in 2023, then fell by 14.63% to $156.6 million in 2024, then decreased by 26.45% to $143.9 million in 2025.
  • Its Short-term Investments stands at $143.9 million for Q3 2025, versus $118.1 million for Q2 2025 and $145.0 million for Q1 2025.